Compare LYEL & CBFV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | CBFV |
|---|---|---|
| Founded | 2018 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.8M | 189.9M |
| IPO Year | 2021 | 2014 |
| Metric | LYEL | CBFV |
|---|---|---|
| Price | $10.91 | $39.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $37.88 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 147.0K | 3.0K |
| Earning Date | 11-11-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 2.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.54 |
| Revenue | $36,000.00 | ★ $43,557,000.00 |
| Revenue This Year | N/A | $15.58 |
| Revenue Next Year | N/A | $8.97 |
| P/E Ratio | ★ N/A | $26.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.20 | $31.72 |
| 52 Week High | $45.00 | $40.39 |
| Indicator | LYEL | CBFV |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 66.11 |
| Support Level | $7.20 | $35.71 |
| Resistance Level | $15.38 | N/A |
| Average True Range (ATR) | 0.79 | 0.71 |
| MACD | 0.43 | 0.26 |
| Stochastic Oscillator | 86.10 | 88.60 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.